

WHAT IS CLAIMED IS: CLAIMS

1. A combination comprising:
 - (a) an anti-CD19 agent; and
 - (b) a B cell targeting agent.
2. The combination of claim 1, wherein the anti-CD19 agent is a CD19 binding molecule.
3. The combination of claim 2, wherein the CD19 binding molecule comprises:
 - (a) CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16;
 - (b) CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19;
 - (c) CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO:20, SEQ ID NO:21, and SEQ ID NO:22; or
 - (d) CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO:23, SEQ ID NO:24, and SEQ ID NO:25.
4. The combination of claim 3, wherein the CD19 binding molecule comprises a VH having the amino acid sequence of SEQ ID NO:13 and/or a VL having the amino acid sequence of SEQ ID NO:26.
5. The combination of claim 2, wherein the CD19 binding molecule comprises:
 - (a) CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO:27, SEQ ID NO:28, and SEQ ID NO:29, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO:40, SEQ ID NO:41, and SEQ ID NO:42;
 - (b) CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO:30, SEQ ID NO:31, and SEQ ID NO:32, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO:43, SEQ ID NO:44, and SEQ ID NO:45;

(c) CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO:33, SEQ ID NO:34, and SEQ ID NO:35, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO:46, SEQ ID NO:47, and SEQ ID NO:48; or

(d) CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO:36, SEQ ID NO:37, and SEQ ID NO:38, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO:49, SEQ ID NO:50, and SEQ ID NO:51.

6. The combination of claims 5, wherein the CD19 binding molecule comprises a VH having the amino acid sequence of SEQ ID NO:39 and/or a VL having the amino acid sequence of SEQ ID NO:52.

7. The combination of any one of claims 2 to 6, wherein the CD19 binding molecule comprises an antibody, an antibody fragment, an scFv, a dsFv, a Fv, a Fab, an scFab, a (Fab')₂, or a single domain antibody (SDAB).

8. The combination of claim 7, wherein the CD19 binding molecule comprises an antibody or an antigen-binding domain thereof.

9. The combination of any one of claims 2 to 8, wherein the CD19 binding molecule is a monospecific binding molecule.

10. The combination of any one of claims 2 to 8, wherein the CD19 binding molecule is a multispecific binding molecule (MBM).

11. The combination of claim 10, wherein the CD19 binding molecule comprises
(a) an antigen-binding module 1 (ABM1) that binds specifically to CD19;
and

(b) an antigen-binding module 2 (ABM2) that binds specifically to a different target molecule.

12. The combination of claim 11, in which ABM2 binds specifically to a component of a human T-cell receptor (TCR) complex.

13. The combination of claim 12, wherein the component of the TCR complex is CD3.

14. The combination of claim 13, wherein ABM2 comprises the CDR sequences of CD3hi.

15. The combination of claim 13, wherein ABM2 comprises the heavy and light chain variable sequences of CD3hi, as set forth in Table 9A.

16. The combination of any one of claims 10 to 15, where the CD19 binding molecule is a bispecific binding molecule (BBM).

17. The combination of any one of claims 11 to 15, wherein the CD19 binding molecule is a trispecific binding molecule (TBM) comprising an antigen-binding module 3 (ABM3) that binds specifically to a target molecule other than CD19.

18. The combination of claim 17, in which ABM2 binds specifically to a component of a human T-cell receptor (TCR) complex and ABM3 binds specifically to (i) human CD2 or (ii) a tumor associated antigen (TAA).

19. The combination of claim 17 or claim 18, which is trivalent.

20. The combination of any one of claims 17 to 19, wherein ABM3 binds specifically to human CD2.

21. The combination of claim 20, wherein ABM3 is a CD58 moiety.

22. The combination of claim 21, wherein the CD58 moiety comprises the amino acid sequence of CD58-6 as set forth in Table 12.

23. The combination of any one of claims 10 to 22, wherein the CD19 binding molecule comprises a first variant Fc region and a second variant Fc region that together form an Fc heterodimer.

24. The combination of claim 2, wherein the CD19 binding molecule is trispecific binding molecule (TBM) comprising:

(a) an antigen-binding module 1 (ABM1) that binds specifically to CD19 and comprises CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19;

(b) an antigen-binding module 2 (ABM2) that binds specifically to a component of a human T-cell receptor (TCR) complex; and

(c) an antigen-binding module 3 (ABM3) that binds specifically to human CD2.

25. The combination of claim 24, wherein the CD19 binding molecule is trivalent.

26. The combination of claim 24 or 25, in which ABM1 is a Fab.

27. The combination of any one of claims 24 to 26, wherein ABM1 comprises a VH having the amino acid sequence of SEQ ID NO:13 and a VL having the amino acid sequence of SEQ ID NO:26.

28. The combination of any one of claims 24 to 27, wherein the component of the TCR complex is CD3.

29. The combination of claim 28, wherein ABM2 is an anti-CD3 antibody or an antigen-binding domain thereof.

30. The combination of claim 29, wherein ABM2 comprises the CDR sequences of CD3hi.

31. The combination of claim 29 or 30, wherein ABM2 comprises the heavy and light chain variable sequences of CD3hi, as set forth in Table 9A.

32. The combination of any one of claims 29 to 31, wherein the anti-CD3 antibody or antigen-binding domain thereof is in the form of a scFv.

33. The combination of claim 32, wherein ABM2 comprises the amino acid sequence of the scFv designated as CD3hi in Table 9A.

34. The combination of any one of claims 24 to 33, wherein ABM3 is a CD58 moiety.

35. The combination of any one of claims 24 to 34, wherein ABM3 comprises the amino acid sequence of CD58-6 as set forth in Table 12.

36. The combination of any one of claims 24 to 35, which comprises an Fc domain.

37. The combination of any one of claims 24 to 35, which comprises a first variant Fc region and a second variant Fc region that together form an Fc heterodimer.

38. The combination of claim 37, wherein the first variant Fc region is a variant human IgG1 Fc region and the second variant Fc region is a variant human IgG1 Fc region, wherein the first and second variant Fc regions comprise L234A, L235A, and G237A ("LALAGA") substitutions, L234A, L235A, S267K, and P329A ("LALASKPA") substitutions, D265A, P329A, and S267K ("DAPASK") substitutions, G237A, D265A, and P329A ("GADAPA") substitutions, G237A, D265A, P329A, and S267K ("GADAPASK") substitutions, L234A, L235A, and P329G ("LALAPG") substitutions, or L234A, L235A, and P329A ("LALAPA") substitutions, wherein the amino acid residues are numbered according to the EU numbering system.

39. The combination of claim 2, wherein the CD19 binding molecule is a trispecific binding molecule (TBM) comprising:

- (a) an antigen-binding module 1 (ABM1) that binds specifically to CD19 and which is a Fab comprising: (i) CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19; or (ii) CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO:30, SEQ ID NO:31, and SEQ ID NO:32, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO:43, SEQ ID NO:44, and SEQ ID NO:45;
- (b) an antigen-binding module 2 (ABM2) that binds specifically to CD3 and which comprises the amino acid sequence of the scFv designated as CD3hi in Table 9A;
- (c) an antigen-binding module 3 (ABM3) that binds specifically to human CD2 and which comprises the amino acid sequence of CD58-6 as set forth in Table 12; and
- (d) an Fc domain.

40. The combination of claim 2, wherein the CD19 binding molecule comprises:

- (a) first half antibody heavy chain whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:63 and a Fc sequence;
- (b) a first half antibody light chain whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:64;

(c) a second half antibody whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:65 and a Fc sequence.

41. The combination of claim 2, wherein the CD19 binding molecule comprises:

(a) a first polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:74;

(b) a second polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:64; and

(c) a third polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:75 or SEQ ID NO:86.

42. The combination of claim 2, wherein the CD19 binding molecule comprises:

(a) a first polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:76;

(b) a second polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:64; and

(c) a third polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:75 or SEQ ID NO:86.

43. The combination of claim 2, wherein the CD19 binding molecule comprises:

(a) a first polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:74;

(b) a second polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:64; and

(c) a third polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:86.

44. The combination of claim 2, wherein the CD19 binding molecule comprises:

(a) a first polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1120;

(b) a second polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1122; and

(c) a third polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1110.

45. The combination of claim 2, wherein the CD19 binding molecule comprises:
(a) a first polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1127;

(b) a second polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1129; and

(c) a third polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1110.

46. The combination of claim 2, wherein the CD19 binding molecule comprises:
(a) a first polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1124;

(b) a second polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1126; and

(c) a third polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1110.

47. The combination of claim 2, wherein the CD19 binding molecule comprises:
(a) a first polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1134;

(b) a second polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1135; and

(c) a third polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1110.

48. The combination of claim 2, wherein the CD19 binding molecule comprises:
(a) a first polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1136;

(b) a second polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1137; and

(c) a third polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1110.

49. The combination of claim 2, wherein the CD19 binding molecule comprises:
(a) a first polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1138;

- (b) a second polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1139; and
- (c) a third polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1110.

50. The combination of claim 2, wherein the CD19 binding molecule comprises:

- (a) a first polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1140;
- (b) a second polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1141; and
- (c) a third polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1110.

51. The combination of claim 2, wherein the CD19 binding molecule comprises:

- (a) a first polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1131;
- (b) a second polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1132; and
- (c) a third polypeptide whose amino acid sequence comprises the amino acid sequence of SEQ ID NO:1133.

52. The combination of claim 2, wherein the CD19 binding molecule is blinatumomab, coltuximab ravtansine, MOR208, MEDI-551, denintuzumab mafodotin, DI-B4, taplitumomabpaptox, XmAb 5871, AFM11, MDX-1342, AFM11, loncastuximab tesirine, or GBR401.

53. The combination of claim 1, wherein the anti-CD19 agent is a population of cells that expresses a chimeric antigen receptor ("CAR") molecule that binds CD19 ("a CAR composition").

54. The combination of claim 53, wherein the CAR composition is tisagenlecleucel, axicabtagene ciloleucel, lisocabtagene maraleucel, or brexucabtagene autoleucel.

55. The combination of claim 54, wherein the CAR composition is tisagenlecleucel.

56. The combination of any one of claims 1 to 55, wherein the B cell targeting agent is a B cell depleting agent.

57. The combination of any one of claims 1 to 56, wherein the B cell targeting agent is a BAFF receptor (BAFFR) binding molecule.

58. The combination of claim 57, wherein the BAFFR binding molecule is an antibody or antigen-binding domain thereof.

59. The combination of claim 57 or 58, wherein the BAFFR binding molecule comprises CDR-H1, CDR-H2, CDR-H3 having the amino acid sequences of ianalumab set forth in Table 18, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of ianalumab set forth in Table 18.

60. The combination of claim 59, wherein the BAFFR binding molecule comprises a heavy chain variable region (VH) and a light chain variable region (VL) having the VH and VL sequences of ianalumab set forth in Table 18.

61. The combination of claim 60, wherein the BAFFR binding molecule is ianalumab.

62. The combination of any one of claims 1 to 56, wherein the B cell targeting agent is a CD20 binding molecule.

63. The combination of claim 62, wherein the CD20 binding molecule is rituximab, ofatumumab, ocrelizumab, veltuzumab, or obinutuzumab.

64. The combination of any one of claims 1 to 56, wherein the B cell targeting agent is a CD22 binding molecule.

65. The combination of claim 64, wherein the CD22 binding molecule is epratuzumab, inotuzumab, or inotuzumab ozogamicin.

66. The combination of any one of claims 1 to 56, wherein the B cell targeting agent is a BAFF binding molecule.

67. The combination of claim 66, wherein the BAFF binding molecule is belimumab, tibulizumab, BR3-Fc, blisibimod or atacicept.

68. The combination of any one of claims 1 to 67, further comprising one or more additional agents.

69. The combination of claim 68, wherein the one or more additional agents comprise a corticosteroid.

70. The combination of claim 69, wherein the corticosteroid is dexamethasone.
71. The combination of any one of claims 68 to 70, wherein the one or more additional agents comprise an immunomodulatory imide drug (IMiD).
72. The combination of claim 71, wherein the immunomodulatory imide drug (IMiD) is lenalidomide, thalidomide, pomalidomide, or iberdomide.
73. The combination of claim 72, wherein the immunomodulatory imide drug (IMiD) is lenalidomide.
74. The combination of any one of claims 1 to 73, wherein the anti-CD19 agent and B cell targeting agent are separate molecules.
75. The combination of any one of claims 1 to 74, wherein the anti-CD19 agent and B cell targeting agent are formulated in separate pharmaceutical compositions
76. The combination of any one of claims 1 to 75 for use in a method of treating a subject having a B cell malignancy.
77. ~~A method of treating a subject having a B cell malignancy, comprising administering~~ Use of the combination of any one of claims 1 to 74 in the manufacture of a medicament for the treatment of a B cell malignancy in a subject, wherein the combination is to be administered to the subject.
78. The combination for use according to claim 76 or ~~method-use~~ of claim 77, wherein ~~the method comprises administering the B cell targeting agent~~ is to be administered to the subject one or more times prior to ~~administering the anti-CD19 agent~~ is to be administered to the subject for the first time.
79. The combination for use or ~~method-use~~ of any one of claims 76 to 78, wherein ~~the method comprises administering the B cell targeting agent~~ is to be administered to the subject a single time prior to ~~administering the anti-CD19 agent~~ is to be administered to the subject for the first time.
80. The combination for use or ~~method-use~~ of any one of claims 76 to 78, wherein ~~the method comprises administering the B cell targeting agent~~ is to be administered to the subject more than one time prior to ~~administering the anti-CD19 agent~~ is to be administered to the subject for the first time.
81. The combination for use according to claim 76 or ~~method-use~~ of claim 77, wherein ~~the method comprises administering simultaneously the B cell targeting agent and the anti-CD19 agent~~ are to be administered simultaneously to the subject.

82. The combination for use or ~~method~~use of any one of claims 76 to 81, wherein the B cell malignancy is a B cell malignancy that expresses cell surface CD19.

83. The combination for use or ~~method~~use of any one of claims 76 to 81, wherein the disease or disorder is non-Hodgkin's lymphoma.

84. The combination for use or ~~method~~use of any one of claims 76 to 81, wherein the disease or disorder is diffuse large B-cell lymphoma (DLBCL).

85. The combination for use or ~~method~~use of any one of claims 76 to 81, wherein the disease or disorder is relapsed and/or refractory DLBCL.

86. The combination for use or ~~method~~use of any one of claims 76 to 81, wherein the disease or disorder is acute lymphoblastic leukemia (ALL).

87. The combination for use or ~~method~~use of any one of claims 76 to 81, wherein the disease or disorder is mantle cell lymphoma (MCL).

88. The combination for use or ~~method~~use of any one of claims 76 to 81, wherein the disease or disorder is Burkitt's lymphoma.

89. The combination for use or ~~method~~use of any one of claims 82 to 88, wherein the subject has failed at least one prior line of standard of care therapy.

90. The combination for use or ~~method~~use of claim 89, wherein the subject has failed up to five prior lines of standard of care therapies.

91. The combination for use or ~~method~~use of claim 89 or claim 90, wherein the subject has failed one prior line of standard of care therapy.

92. The combination for use or ~~method~~use of claim 89 or claim 90, wherein the subject has failed two prior lines of standard of care therapy.

93. The combination for use or ~~method~~use of claim 89 or claim 90, wherein the subject has failed three prior lines of standard of care therapy.

94. The combination for use or ~~method~~use of claim 89 or claim 90, wherein the subject has failed four prior lines of standard of care therapy.

95. The combination for use or ~~method~~use of claim 89 or claim 90, wherein the subject has failed five prior lines of standard of care therapy.

96. The combination for use or ~~method~~use of any one of claims 89 to 95, wherein the at least one prior line of standard of care therapies comprise an anti-CD20 therapy.

97. The combination for use or ~~method~~use of claim 96, wherein the anti-CD20 therapy is rituximab.

98. The combination for use or ~~method~~use of any one of claims 89 to 97, wherein the subject is intolerant to or ineligible for one or more other approved therapies.

99. The combination for use or ~~method~~use of claim 98, wherein the one or more other approved therapies comprise an autologous stem cell transplant (ASCT).

100. The combination for use or ~~method~~use of any one of claims 89 to 99, wherein the subject is a non-responder to a CAR composition.

101. The combination for use or ~~method~~use of claim 100, wherein the CAR composition is an anti-CD19 CAR composition.

102. The combination for use or ~~method~~use of claim 100 or claim 101, wherein the CAR composition comprises CTL019, tisagenlecleucel, axicabtagene ciloleucel, brexucabtagene autoleucel or lisocabtagene maraleucel.

103. The combination for use or ~~method~~use of any one of claims 100 to 102, wherein the anti-CD19 agent does not comprise a chimeric antigen receptor and/or is not a CAR composition.

104. A chimeric antigen receptor ("CAR") molecule that binds CD19, comprising an anti-CD19 binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the anti-CD19 binding domain comprises CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16.

105. A chimeric antigen receptor ("CAR") molecule that binds CD19, comprising an anti-CD19 binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the anti-CD19 binding domain comprises CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO:17, SEQ ID NO:18, and SEQ ID NO:19.

106. A chimeric antigen receptor ("CAR") molecule that binds CD19, comprising an anti-CD19 binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the anti-CD19 binding domain comprises CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO:20, SEQ ID NO:21, and SEQ ID NO:22.

107. A chimeric antigen receptor ("CAR") molecule that binds CD19, comprising an anti-CD19 binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the anti-CD19 binding domain comprises CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO:10, SEQ ID NO:11, and SEQ ID NO:12, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO:23, SEQ ID NO:24, and SEQ ID NO:25.

108. The CAR molecule of any one of claims 104 to 107, wherein the anti-CD19 binding domain comprises a VH having the amino acid sequence of SEQ ID NO:13 and/or a VL having the amino acid sequence of SEQ ID NO:26.

109. A chimeric antigen receptor ("CAR") molecule that binds CD19, comprising an anti-CD19 binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the anti-CD19 binding domain comprises CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO:27, SEQ ID NO:28, and SEQ ID NO:29, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO:40, SEQ ID NO:41, and SEQ ID NO:42.

110. A chimeric antigen receptor ("CAR") molecule that binds CD19, comprising an anti-CD19 binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the anti-CD19 binding domain comprises CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO:30, SEQ ID NO:31, and SEQ ID NO:32, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO:43, SEQ ID NO:44, and SEQ ID NO:45.

111. A chimeric antigen receptor ("CAR") molecule that binds CD19, comprising an anti-CD19 binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the anti-CD19 binding domain comprises CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO:33, SEQ ID NO:34, and SEQ ID NO:35, and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO:46, SEQ ID NO:47, and SEQ ID NO:48.

112. A chimeric antigen receptor ("CAR") molecule that binds CD19, comprising an anti-CD19 binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the anti-CD19 binding domain comprises CDR-H1, CDR-H2, and CDR-H3 having the amino acid sequences of SEQ ID NO:36, SEQ ID NO:37, and SEQ ID NO:38, and CDR-

L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO:49, SEQ ID NO:50, and SEQ ID NO:51.

113. The CAR molecule of any one of claims 109 to 112, wherein the anti-CD19 binding domain comprises a VH having the amino acid sequence of SEQ ID NO: 39 and/or a VL having the amino acid sequence of SEQ ID NO: 52.

114. The combination of claim 57 or 58, wherein the BAFFR binding molecule comprises a CDR-H1, CDR-H2 and CDR-H3 of ivalumab, and a CDR-L1, CDR-L2, and CDR-L3 of ivalumab.

115. The combination of claim 57 or 114, wherein the BAFFR binding molecule comprises a heavy chain variable region (VH) and a light chain variable region (VL) having the VH and VL sequences of ivalumab.

116. The combination of claim 57 or 114 or 115, wherein the BAFFR binding molecule is ivalumab.

117. The combination of claim 57, wherein the BAFFR binding molecule comprises CDR-H1, CDR-H2, CDR-H3 having the amino acid sequences of SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55 respectively and CDR-L1, CDR-L2, and CDR-L3 having the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, SEQ ID NO: 58 respectively.

118. The combination of claim 57 or 117, wherein the BAFFR binding molecule comprises a heavy chain variable region (VH) and a light chain variable region (VL) having the VH sequence of SEQ ID NO: 59 and VL sequence of SEQ ID NO: 60.

119. The combination of claim 57 or 117-118, wherein the BAFFR binding molecule comprises a heavy chain sequence of SEQ ID NO: 61 and a light chain sequence of SEQ ID NO: 62.

120. The combination for use according to claim 76 or ~~method-use~~ of claim 77, wherein ~~the method comprises administering the B cell targeting agent~~ is to be administered prior to ~~administering the anti-CD19 agent~~ is to be administered to the subject.